NASDAQ:BOLT

Bolt Biotherapeutics (BOLT) Stock Forecast, Price & News

$1.70

0.00 (0.00%)

(As of 06/2/2023 ET)

Compare

Today's Range: $1.69
▼
$1.75
50-Day Range: $1.29
▼
$1.95
52-Week Range: $1.18
▼
$2.72

Volume: 18,799 shs
Average Volume: 189,530 shs
Market Capitalization: $64.28 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Bolt Biotherapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 194.1% Upside
$5.00 Price Target
Short Interest: Bearish
6.40% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.02) to ($1.88) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

541st out of 983 stocks

Pharmaceutical Preparations Industry

265th out of 486 stocks

3.3

Analyst's Opinion

Consensus Rating
Bolt Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Bolt Biotherapeutics has a forecasted upside of 194.1% from its current price of $1.70.
Amount of Analyst Coverage
Bolt Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.40% of the float of Bolt Biotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
Bolt Biotherapeutics has a short interest ratio ("days to cover") of 6.3.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Bolt Biotherapeutics does not currently pay a dividend.
Dividend Growth
Bolt Biotherapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BOLT.

1.1

News and Social Media Coverage

Search Interest
8 people have searched for BOLT on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
MarketBeat Follows
2 people have added Bolt Biotherapeutics to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
22.90% of the stock of Bolt Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
71.13% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($2.02) to ($1.88) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bolt Biotherapeutics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bolt Biotherapeutics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bolt Biotherapeutics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bolt Biotherapeutics (NASDAQ:BOLT) Stock

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

BOLT Stock News Headlines

May 26, 2023 | markets.businessinsider.com

Bolt Biotherapeutics (BOLT) Receives a Buy from H.C. Wainwright

May 13, 2023 | msn.com

SVB Leerink Upgrades Bolt Biotherapeutics (BOLT)

June 4, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

May 13, 2023 | msn.com

HC Wainwright & Co. Reiterates Bolt Biotherapeutics (BOLT) Buy Recommendation

May 13, 2023 | americanbankingnews.com

SVB Leerink Upgrades Bolt Biotherapeutics (NASDAQ:BOLT) to Outperform

May 12, 2023 | markets.businessinsider.com

JonesTrading Reaffirms Their Buy Rating on Bolt Biotherapeutics (BOLT)

May 12, 2023 | finanznachrichten.de

Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

April 26, 2023 | finance.yahoo.com

Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

June 4, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

April 11, 2023 | finance.yahoo.com

Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last year

April 5, 2023 | americanbankingnews.com

Brokers Issue Forecasts for Bolt Biotherapeutics, Inc.'s FY2023 Earnings (NASDAQ:BOLT)

April 3, 2023 | americanbankingnews.com

Bolt Biotherapeutics' (BOLT) Buy Rating Reiterated at HC Wainwright

April 2, 2023 | americanbankingnews.com

Bolt Biotherapeutics (NASDAQ:BOLT) & Endonovo Therapeutics (OTCMKTS:ENDVD) Financial Survey

March 31, 2023 | americanbankingnews.com

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Expected to Earn Q1 2023 Earnings of ($0.55) Per Share

March 30, 2023 | finanznachrichten.de

Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 14, 2023 | finance.yahoo.com

Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting

January 21, 2023 | reuters.com

BOLT.O - | Stock Price & Latest News | Reuters

January 4, 2023 | finance.yahoo.com

Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation

November 2, 2022 | finance.yahoo.com

Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 89% over the last year

November 1, 2022 | finance.yahoo.com

Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference

September 10, 2022 | morningstar.com

Bolt Biotherapeutics Inc Ordinary Shares

August 31, 2022 | finance.yahoo.com

Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

August 12, 2022 | benzinga.com

Bolt Biotherapeutics (NASDAQ:BOLT), Earnings Estimates, EPS, and Revenue

May 26, 2022 | finance.yahoo.com

The past year for Bolt Biotherapeutics (NASDAQ:BOLT) investors has not been profitable

March 30, 2022 | finance.yahoo.com

Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights

March 30, 2022 | seekingalpha.com

Bolt Biotherapeutics GAAP EPS of -$0.73 misses by $0.04, revenue of $0.51M

March 8, 2022 | finance.yahoo.com

Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022

See More Headlines

BOLT Price History

30 days | 90 days | 365 days | Advanced Chart

BOLT Company Calendar

Last Earnings: 3/29/2023
Today: 6/04/2023
Next Earnings (Estimated): 8/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:BOLT
CUSIP: 09769810
CIK: 354655
Web: www.boltbio.com
Phone: 650-665-9295
Fax: N/A
Employees: 91
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +194.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-88,100,000.00
Net Margins: -1,207.36%
Pretax Margin: -1,207.36%
Return on Equity: -44.87%
Return on Assets: -34.65%

Debt

Debt-to-Equity Ratio: 0.12
Current Ratio: 8.10
Quick Ratio: 8.10

Sales & Book Value

Annual Sales: $6.74 million
Price / Sales: 9.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.17 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 37,813,000
Free Float: 29,154,000
Market Cap: $64.28 million
Optionable: Not Optionable
Beta: 1.02

Key Executives

Dr. Randall C. Schatzman Ph.D. (Age 68)
CEO & Director
Comp: $830.67k

Dr. Edgar G. Engleman M.D. (Age 77)
Founder & Independent Director
Comp: $31.58k

Mr. William P. Quinn (Age 52)
CFO & Sec.
Comp: $563.68k

Mr. Grant Yonehiro C.F.A. (Age 59)
M.B.A., Chief Bus. Officer
Comp: $519.98k

Dr. Edith A. Perez M.D. (Age 66)
Chief Medical Officer
Comp: $627.32k

Ms. Karen L. Bergman
VP of Communications & Investor Relations

Mr. Wesley Burwell
VP & Head of HR

Dr. Nathan Ihle Ph.D.
Sr. VP of Pharmaceutical Operations

Dr. Ming Yin Ph.D.
VP & Head of Biometrics

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BOLT Stock - Frequently Asked Questions

Should I buy or sell Bolt Biotherapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BOLT shares.
View BOLT analyst ratings or view top-rated stocks.
What is Bolt Biotherapeutics' stock price forecast for 2023?: 3 Wall Street research analysts have issued 12 month price targets for Bolt Biotherapeutics' shares. Their BOLT share price forecasts range from $3.00 to $8.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 194.1% from the stock's current price.
View analysts price targets for BOLT or view top-rated stocks among Wall Street analysts.
How have BOLT shares performed in 2023?: Bolt Biotherapeutics' stock was trading at $1.30 on January 1st, 2023. Since then, BOLT shares have increased by 30.8% and is now trading at $1.70.
View the best growth stocks for 2023 here.
When is Bolt Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our BOLT earnings forecast.
How were Bolt Biotherapeutics' earnings last quarter?: Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) issued its quarterly earnings results on Wednesday, March, 29th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.10. The company earned $1.41 million during the quarter, compared to analysts' expectations of $1.71 million. Bolt Biotherapeutics had a negative trailing twelve-month return on equity of 44.87% and a negative net margin of 1,207.36%.
Is Bolt Biotherapeutics a good dividend stock?: Bolt Biotherapeutics (NASDAQ:BOLT) pays an annual dividend of $0.36 per share and currently has a dividend yield of 0.00%.

What other stocks do shareholders of Bolt Biotherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP).
When did Bolt Biotherapeutics IPO?: (BOLT) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.
What is Bolt Biotherapeutics' stock symbol?: Bolt Biotherapeutics trades on the NASDAQ under the ticker symbol "BOLT."
Who are Bolt Biotherapeutics' major shareholders?: Bolt Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.21%), JPMorgan Chase & Co. (0.50%), Geode Capital Management LLC (0.47%), Bailard Inc. (0.08%) and Charles Schwab Investment Management Inc. (0.07%). Insiders that own company stock include Edgar Engleman, Holdings A/S Novo, Randall C Schatzman, Vivo Capital Fund Viii, LP and William P Quinn.
View institutional ownership trends.
How do I buy shares of Bolt Biotherapeutics?: Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Bolt Biotherapeutics' stock price today?: One share of BOLT stock can currently be purchased for approximately $1.70.
How much money does Bolt Biotherapeutics make?: Bolt Biotherapeutics (NASDAQ:BOLT) has a market capitalization of $64.28 million and generates $6.74 million in revenue each year. The company earns $-88,100,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.
How can I contact Bolt Biotherapeutics?: Bolt Biotherapeutics' mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.boltbio.com. The company can be reached via phone at 650-665-9295 or via email at sarah.mccabe@sternir.com.

This page (NASDAQ:BOLT) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial